Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by HMG-CoA reductase inhibitor

Similar Items

• Predictive Modeling of Secondary Pulmonary Hypertension in Left Ventricular Diastolic Dysfunction
  od: Harrod, Karlyn K., i dr.
  Izdano: (2021)
• Pulmonary Hypertension Secondary to Left Ventricular Systolic Dysfunction: Contemporary Diagnosis and Management
  od: Shah, Ravi V., i dr.
  Izdano: (2008)
• The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction
  od: Chen, I-Chen, i dr.
  Izdano: (2020)
• Left ventricular dysfunction in COPD without pulmonary hypertension
  od: Hilde, Janne M., i dr.
  Izdano: (2020)
• The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
  od: Gelosa, Paolo, i dr.
  Izdano: (2007)